Shares of SELLAS Life Sciences Group surged 9.5% on Monday, reaching a high of $4.46, driven by positive analyst sentiment regarding its cancer immunotherapy pipeline. While Maxim Group raised its price target from $7 to $10 and maintained a ‘buy’ rating, Weiss Ratings upheld a ‘sell’ rating, reflecting mixed views among analysts. Despite the stock’s upswing, cautious investor sentiment remains as SELLAS continues its clinical development, especially for its lead candidate, galinpepimut-S (GPS).
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://nationaltoday.com/us/ma/waltham/news/2026/04/06/sellas-life-sciences-group-stock-jumps-9-5/
